Wilson Liao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wilson Liao has a total of 866 co-authors. Here are the top co-authors by number of shared publications:
Tina Bhutani
Department of Dermatology, University of California, San Francisco, San Francisco, California, USA
41 shared publications- Tina Bhutani
Department of Dermatology, University of California San Francisco, San Francisco, California, USA
24 shared publications Marwa Hakimi
Department of Dermatology, University of California, San Francisco, San Francisco, California, USA
18 shared publications- Allison Kranyak
Department of Dermatology, University of California San Francisco, San Francisco, USA
15 shared publications - Joy Q. Jin
University of California at San Francisco
14 shared publications - Richard Ahn
Department of Dermatology, University of California, San Francisco, San Francisco, CA, United States
11 shared publications
Latest Publications
- Open Access
High-resolution analysis of T cell subsets, clonality, and trajectories in psoriasis
Psoriasis is sustained by type 17 immunity, yet how transcriptionally defined T-cell states are clonally organized across lesions, clinically uninvolved skin, and the circulation remains incompletely understood. We performed paired single-cell RNA and T-cell receptor (TCR) sequencing of T cells isolated from two spatially separated lesions, non-lesional skin, and peripheral blood from 23 participants with psoriasis, together with healthy skin and blood comparators. We resolved 19 cutaneous T-cell populations and found that lesions were enriched for IL-17-associated CD4+ and CD8+ states and activated regulatory T-cell states. CD8+ Tc17 cells showed prominent clonal expansion, and expanded clonotypes contributed more prominently to skin than to blood. Clonotype sharing was greatest between paired lesions, while clonotypes detected in cutaneous IL-17-associated cells mapped to multiple circulating phenotypes, indicating that blood and skin capture complementary features of the disease-associated repertoire. At the sample level, T-cell composition separated 57 lesional samples into two recurrent compositional states that were largely concordant across paired body sites. HLA-C*06:02 status was associated with differences in pretreatment lesional CD8+ T-cell composition, clonotype overlap, and clonal-size distributions. Exploratory longitudinal analyses in eight treated participants showed heterogeneous remodeling of T-cell composition and clonotype detection after therapy. Together, these findings define tissue-restricted and tissue-shared features of the psoriatic T-cell repertoire and identify clonal architecture across skin sites and blood as an organizing feature of lesion heterogeneity.
Open AccessHigh-resolution analysis of T cell subsets, clonality, and trajectories in psoriasis
Psoriasis is sustained by type 17 immunity, yet how transcriptionally defined T-cell states are clonally organized across lesions, clinically uninvolved skin, and the circulation remains incompletely understood. We performed paired single-cell RNA and T-cell receptor (TCR) sequencing of T cells isolated from two spatially separated lesions, non-lesional skin, and peripheral blood from 23 participants with psoriasis, together with healthy skin and blood comparators. We resolved 19 cutaneous T-cell populations and found that lesions were enriched for IL-17-associated CD4+ and CD8+ states and activated regulatory T-cell states. CD8+ Tc17 cells showed prominent clonal expansion, and expanded clonotypes contributed more prominently to skin than to blood. Clonotype sharing was greatest between paired lesions, while clonotypes detected in cutaneous IL-17-associated cells mapped to multiple circulating phenotypes, indicating that blood and skin capture complementary features of the disease-associated repertoire. At the sample level, T-cell composition separated 57 lesional samples into two recurrent compositional states that were largely concordant across paired body sites. HLA-C*06:02 status was associated with differences in pretreatment lesional CD8+ T-cell composition, clonotype overlap, and clonal-size distributions. Exploratory longitudinal analyses in eight treated participants showed heterogeneous remodeling of T-cell composition and clonotype detection after therapy. Together, these findings define tissue-restricted and tissue-shared features of the psoriatic T-cell repertoire and identify clonal architecture across skin sites and blood as an organizing feature of lesion heterogeneity.
- Open Access
- 8 September 2026
- Published by Dermsquared in SKIN The Journal of Cutaneous Medicine
- Vol. 10 (5) , 3408-3412
Itch Is Now Made Visible: Advances in fMRI and Its Relevance to Dermatology
Pruritus has long presented a diagnostic paradox in dermatology. Despite being among the most frequent patient complaints, it remains undervalued when unaccompanied by visible pathology. Bias toward visual cues in the field has often resulted in a tendency toward systematic neglect during clinical evaluation, and patients presenting with pruritus of unknown origin are frequently mischaracterized with factitious conditions. However, recent neuroimaging advances are revolutionizing our approach to pruritus by rendering central nervous system (CNS) itch pathways directly observable through functional magnetic resonance imaging (fMRI). Pioneering investigations have captured the neural signatures of centrally-originating pruritus, including socially-triggered, contagious itch and expectation-amplified itch through nocebo mechanisms. These studies reveal distinct brain activation patterns and have mapped core CNS-itch circuitry. Such neuroimaging capabilities hold promise for developing objective itch biomarkers, stratifying treatment candidates, and providing objective visual validation of patient-reported symptoms.
- 8 September 2026
- Published by Dermsquared in SKIN The Journal of Cutaneous Medicine
- Vol. 10 (5) , 3408-3412
Open AccessItch Is Now Made Visible: Advances in fMRI and Its Relevance to Dermatology
Pruritus has long presented a diagnostic paradox in dermatology. Despite being among the most frequent patient complaints, it remains undervalued when unaccompanied by visible pathology. Bias toward visual cues in the field has often resulted in a tendency toward systematic neglect during clinical evaluation, and patients presenting with pruritus of unknown origin are frequently mischaracterized with factitious conditions. However, recent neuroimaging advances are revolutionizing our approach to pruritus by rendering central nervous system (CNS) itch pathways directly observable through functional magnetic resonance imaging (fMRI). Pioneering investigations have captured the neural signatures of centrally-originating pruritus, including socially-triggered, contagious itch and expectation-amplified itch through nocebo mechanisms. These studies reveal distinct brain activation patterns and have mapped core CNS-itch circuitry. Such neuroimaging capabilities hold promise for developing objective itch biomarkers, stratifying treatment candidates, and providing objective visual validation of patient-reported symptoms.
- Open Access
- 4 August 2026
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 37 (1)
Increasing formulary adoption of adalimumab biosimilars and differential cost-sharing in Medicare Part D plans
Adalimumab is one of the most widely prescribed specialty therapies in dermatology and is also associated with high annual cost burdens. However, the loss of exclusivity and subsequent US market en...
- 4 August 2026
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 37 (1)
Open AccessIncreasing formulary adoption of adalimumab biosimilars and differential cost-sharing in Medicare Part D plans
Adalimumab is one of the most widely prescribed specialty therapies in dermatology and is also associated with high annual cost burdens. However, the loss of exclusivity and subsequent US market en...
- Open Access
- 11 July 2026
- Published by Elsevier in Journal of Investigative Dermatology
Clinical and genetic characterization of genital and inverse psoriasis as a distinct psoriasis endotype
- 11 July 2026
- Published by Elsevier in Journal of Investigative Dermatology
Open AccessClinical and genetic characterization of genital and inverse psoriasis as a distinct psoriasis endotype
- 23 June 2026
- Published by SAGE Publications in Journal of Psoriasis and Psoriatic Arthritis®
Exploring the Gut Microbiome’s Association in Psoriasis and Psoriatic Arthritis: A Scoping Review
Introduction: Psoriasis (PsO) and psoriatic arthritis (PsA) are chronic inflammatory conditions treated with primarily immune-modulating medication. However, interest is growing in gut microbiome therapies. Studies have reported altered gut microbiota in PsO/PsA and explored probiotics and fecal microbiota transplantation (FMT) as potential therapies. This review synthesizes global studies on the microbiome’s associations in PsO/PsA. Methods: We conducted a scoping literature review to understand the association between gut microbiota in PsO and PsA patients. Pubmed was used to identify 4,126 published manuscripts between 2015-2025. Thirty studies were included, encompassing 749,275 participants, with balanced gender representation and ages ranging from 18 to 76 years. These studies included 21 case-control studies, 1 case-series, 2 genome-wide analyses, 5 clinical trials, and 1 retrospective review. Results: Eighteen studies reported significant gut microbiome differences in PsO/PsA vs healthy controls. Variation in the Firmicutes/Bacteroides (F/B) ratio was of interest, with one study suggesting a low F/B ratio and five studies suggesting an elevated F/B ratio in PsO. A higher F/B ratio was linked to increased acetate production. Acetate and propionate, key short-chain fatty acids (SCFAs), were associated with modulation of the IL-23/Th17 axis in psoriasis and activation of keratinocytes. The role of therapeutics targeting the gut microbiome was explored. Ustekinumab and tofacitinib altered gut microbiome composition. Probiotic and FMT interventions showed mixed outcomes. Six of eight probiotic studies reported increased SCFA producing species and/or reduced inflammatory markers. FMT improved immune markers in mice but had no significant benefit in human trials. Conclusion: Alterations in the microbiome linked to inflammation and immune response, suggest the microbiome as a potential therapeutic target for PsO/PsA.
- 23 June 2026
- Published by SAGE Publications in Journal of Psoriasis and Psoriatic Arthritis®
Exploring the Gut Microbiome’s Association in Psoriasis and Psoriatic Arthritis: A Scoping Review
Introduction: Psoriasis (PsO) and psoriatic arthritis (PsA) are chronic inflammatory conditions treated with primarily immune-modulating medication. However, interest is growing in gut microbiome therapies. Studies have reported altered gut microbiota in PsO/PsA and explored probiotics and fecal microbiota transplantation (FMT) as potential therapies. This review synthesizes global studies on the microbiome’s associations in PsO/PsA. Methods: We conducted a scoping literature review to understand the association between gut microbiota in PsO and PsA patients. Pubmed was used to identify 4,126 published manuscripts between 2015-2025. Thirty studies were included, encompassing 749,275 participants, with balanced gender representation and ages ranging from 18 to 76 years. These studies included 21 case-control studies, 1 case-series, 2 genome-wide analyses, 5 clinical trials, and 1 retrospective review. Results: Eighteen studies reported significant gut microbiome differences in PsO/PsA vs healthy controls. Variation in the Firmicutes/Bacteroides (F/B) ratio was of interest, with one study suggesting a low F/B ratio and five studies suggesting an elevated F/B ratio in PsO. A higher F/B ratio was linked to increased acetate production. Acetate and propionate, key short-chain fatty acids (SCFAs), were associated with modulation of the IL-23/Th17 axis in psoriasis and activation of keratinocytes. The role of therapeutics targeting the gut microbiome was explored. Ustekinumab and tofacitinib altered gut microbiome composition. Probiotic and FMT interventions showed mixed outcomes. Six of eight probiotic studies reported increased SCFA producing species and/or reduced inflammatory markers. FMT improved immune markers in mice but had no significant benefit in human trials. Conclusion: Alterations in the microbiome linked to inflammation and immune response, suggest the microbiome as a potential therapeutic target for PsO/PsA.
- Open Access
- 26 May 2026
- Published by Elsevier in JAAD Case Reports
- Vol. 74, 70-74
Modified Goeckerman therapy for chronic skin diseases in a resource-limited setting: A case series from Kenya
- 26 May 2026
- Published by Elsevier in JAAD Case Reports
- Vol. 74, 70-74
Open AccessModified Goeckerman therapy for chronic skin diseases in a resource-limited setting: A case series from Kenya
- 15 May 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (Suppl 2) , 28-32
GRAPPA 2025 Annual Meeting: Advances in Psoriatic Disease Research From Pilot Grant Awardees
Key advances from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) pilot research grant program were presented at the GRAPPA 2025 annual meeting. Areas of study included hypoxia-inducible factor 1α (HIF1A) as a potential factor in psoriatic arthritis (PsA), plasma extracellular vesicle cytokines as potential biomarkers for predicting response to tumor necrosis factor inhibitors in PsA, bone properties and biomechanics in psoriatic disease (PsD), better understanding of differences in body composition in PsD, and the effect of sleep on PsD severity.
- 15 May 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (Suppl 2) , 28-32
GRAPPA 2025 Annual Meeting: Advances in Psoriatic Disease Research From Pilot Grant Awardees
Key advances from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) pilot research grant program were presented at the GRAPPA 2025 annual meeting. Areas of study included hypoxia-inducible factor 1α (HIF1A) as a potential factor in psoriatic arthritis (PsA), plasma extracellular vesicle cytokines as potential biomarkers for predicting response to tumor necrosis factor inhibitors in PsA, bone properties and biomechanics in psoriatic disease (PsD), better understanding of differences in body composition in PsD, and the effect of sleep on PsD severity.
- 15 May 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (Suppl 2) , 4-6
GRAPPA 2025 Collaborative Research Network Meeting: Difficult-to-Treat Psoriatic Arthritis and Future Strategies for Curing Psoriasis
At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2025 Collaborative Research Network meeting in Bogotá, Colombia, experts in dermatology and rheumatology presented complementary perspectives on the future of psoriatic disease management. Dr. Andrew Blauvelt introduced innovative approaches to achieving long-term remission or a cure for psoriasis, focusing on early intervention and "knockout" therapies with high-dose interleukin 23 inhibitors. Dr. Philip Mease presented evolving concepts in difficult-to-treat and complex-to-manage psoriatic arthritis, emphasizing the need for formal definitions and the growing role of dual therapy strategies. This session reflected a shift toward a more personalized, proactive, and multidisciplinary strategy to address unmet needs in psoriatic disease.
- 15 May 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (Suppl 2) , 4-6
GRAPPA 2025 Collaborative Research Network Meeting: Difficult-to-Treat Psoriatic Arthritis and Future Strategies for Curing Psoriasis
At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2025 Collaborative Research Network meeting in Bogotá, Colombia, experts in dermatology and rheumatology presented complementary perspectives on the future of psoriatic disease management. Dr. Andrew Blauvelt introduced innovative approaches to achieving long-term remission or a cure for psoriasis, focusing on early intervention and "knockout" therapies with high-dose interleukin 23 inhibitors. Dr. Philip Mease presented evolving concepts in difficult-to-treat and complex-to-manage psoriatic arthritis, emphasizing the need for formal definitions and the growing role of dual therapy strategies. This session reflected a shift toward a more personalized, proactive, and multidisciplinary strategy to address unmet needs in psoriatic disease.
- Open Access
- 11 May 2026
- Published by Dermsquared in SKIN The Journal of Cutaneous Medicine
- Vol. 10 (3) , 3072-3081
Patient Characteristics and Treatment Approaches in Delusional Infestation Across Two Medical Centers: A Retrospective Study
Background: Delusional Infestation (DI) is a psychiatric disorder marked by persistent, false belief of infestation despite medical evidence to the contrary. Large-scale research on DI is limited, with only one population-based study to date. DI remains poorly understood and difficult to manage. Methods: We conducted a multicenter retrospective chart review of adult outpatients seen in tertiary dermatology clinics at the University of Michigan and University of California, San Francisco between January 2021 and May 2024. Patients were identified using relevant ICD codes, and eligibility was confirmed by manual review for DSM-5 criteria for DI. Key clinical and demographic data were extracted, and relevant risk was calculated using national prevalence data from NAMI and SAMHSA. Results: We identified 155 patients with DI; most were female (79%), non-Hispanic (94%), and white (73%). Mean age of onset was 54 years, with a three-year diagnostic delay. Delusions commonly involved parasites (25%) or bugs/insects (27%). Diagnostic evaluations included skin biopsy (34%) and skin scrapings (15%), with significant variation between centers. Substance use and psychiatric comorbidities were prevalent, with elevated relative risks compared to population data. Treatments most often involved antiparasitic agents, pimozide, or second-generation antipsychotics; pimozide was associated with the highest rate of improvement Conclusions: DI primarily affects middle-aged female and is marked by delayed diagnosis, frequent substance use, and psychiatric comorbidities. Despite varied diagnostic approaches, treatment outcomes remain poor. Multidisciplinary care and standardized protocols are needed to improve management and outcomes.
- 11 May 2026
- Published by Dermsquared in SKIN The Journal of Cutaneous Medicine
- Vol. 10 (3) , 3072-3081
Open AccessPatient Characteristics and Treatment Approaches in Delusional Infestation Across Two Medical Centers: A Retrospective Study
Background: Delusional Infestation (DI) is a psychiatric disorder marked by persistent, false belief of infestation despite medical evidence to the contrary. Large-scale research on DI is limited, with only one population-based study to date. DI remains poorly understood and difficult to manage. Methods: We conducted a multicenter retrospective chart review of adult outpatients seen in tertiary dermatology clinics at the University of Michigan and University of California, San Francisco between January 2021 and May 2024. Patients were identified using relevant ICD codes, and eligibility was confirmed by manual review for DSM-5 criteria for DI. Key clinical and demographic data were extracted, and relevant risk was calculated using national prevalence data from NAMI and SAMHSA. Results: We identified 155 patients with DI; most were female (79%), non-Hispanic (94%), and white (73%). Mean age of onset was 54 years, with a three-year diagnostic delay. Delusions commonly involved parasites (25%) or bugs/insects (27%). Diagnostic evaluations included skin biopsy (34%) and skin scrapings (15%), with significant variation between centers. Substance use and psychiatric comorbidities were prevalent, with elevated relative risks compared to population data. Treatments most often involved antiparasitic agents, pimozide, or second-generation antipsychotics; pimozide was associated with the highest rate of improvement Conclusions: DI primarily affects middle-aged female and is marked by delayed diagnosis, frequent substance use, and psychiatric comorbidities. Despite varied diagnostic approaches, treatment outcomes remain poor. Multidisciplinary care and standardized protocols are needed to improve management and outcomes.
- Open Access
- 19 April 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (2) , 540-542
Interchangeability on formulary coverage of adalimumab biosimilars in Medicare part D
- 19 April 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (2) , 540-542
Open AccessInterchangeability on formulary coverage of adalimumab biosimilars in Medicare part D